Evolution of resistance to cancer therapy

Franziska Michor, Martin A. Nowak, Yoh Iwasa

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.

Original languageEnglish
Pages (from-to)261-271
Number of pages11
JournalCurrent Pharmaceutical Design
Volume12
Issue number3
DOIs
Publication statusPublished - Jan 1 2006

Fingerprint

Neoplasms
Pharmaceutical Preparations
Therapeutics
Drug Resistance
Epigenomics
Pressure
Drug Therapy
Mutation
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Evolution of resistance to cancer therapy. / Michor, Franziska; Nowak, Martin A.; Iwasa, Yoh.

In: Current Pharmaceutical Design, Vol. 12, No. 3, 01.01.2006, p. 261-271.

Research output: Contribution to journalReview article

Michor, Franziska ; Nowak, Martin A. ; Iwasa, Yoh. / Evolution of resistance to cancer therapy. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 3. pp. 261-271.
@article{7ecc99d38cab486497c81fcb81afacd8,
title = "Evolution of resistance to cancer therapy",
abstract = "Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.",
author = "Franziska Michor and Nowak, {Martin A.} and Yoh Iwasa",
year = "2006",
month = "1",
day = "1",
doi = "10.2174/138161206775201956",
language = "English",
volume = "12",
pages = "261--271",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Evolution of resistance to cancer therapy

AU - Michor, Franziska

AU - Nowak, Martin A.

AU - Iwasa, Yoh

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.

AB - Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.

UR - http://www.scopus.com/inward/record.url?scp=33644871485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644871485&partnerID=8YFLogxK

U2 - 10.2174/138161206775201956

DO - 10.2174/138161206775201956

M3 - Review article

C2 - 16454743

AN - SCOPUS:33644871485

VL - 12

SP - 261

EP - 271

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 3

ER -